Drug-Resistant Malaria - libdoc.who.int - World Health Organization

Table 9. Suggested Use of Antimalarial Drugs in Areas With or Without Drug Resistance(l) (cont'd)
Adult doses, to be adjusted for age, See Appendix 5 for detailed description of alternative drug regimens)
Areas where chloroquine- Areas where chloroquine- Areas without chloroquine-
Type of treatment resistant P.falciparum resistant P.falciparum resistant P.falciparum
is well established (2) is emerging and not serious~threatened
by its potential spread
(sulfadoxine + pyrimethamine
resistant)
Sulfadoxine 500 mg + pyrimethamine
25 mg once weekly
or
dapsone 100 mg + pyrimethamine (Not applicable) (Not applicable)
12.5 mg once weekly
(with chloroquine 300 mg weekly as
protection against species other
than P.falciparum where they are
resistant to pyrimethamine)
With personal anti-vector precautions.
Constult experienced physician
if fever occurs.
Note
(1) Intended primarily for the South-East Asia and Western Pacific Regions and not necessarily applicable to other Regions.
(2) At present it is not possible to define a generally applicable criterion for discontinuation of the use of chloroquine in
clinical presumptive treatment. Research is urgently required.
For the time being this decision should be made by health authorities based on the best local information.
(3) For definitions, see WHO TRS No.529 (1973).
(4) In areas where treatment of clinical cases is the only measure of malaria control, it may be essential to retain chloroquine
in addition.
(5) If option A has to be used in areas with a significant proportion of species other than P.falciparum, chloroquine 600 mg
should also be used. ---- .-------
(6) Mefloquine by itself must not be used for mass drug administration.
(')
o
~
~
t-'
......
0'
\0